KLKe Li

Ke Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ke Li has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Changcheng Zhu

    Institute of Drug Research and Development, Kunming Pharmaceutical Corporation, Kunming 650100, PR China

    2 shared publications
  • Conghai Zhang

    Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China

    2 shared publications
  • Dandan Li

    State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Sun Yat‐Sen University Guangzhou China

    2 shared publications
  • Huatao Niu

    Department of Neurosurgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province

    2 shared publications
  • Jihong Zhang

    Laboratory of Molecular Genetics of Aging and Tumor, Medical School, Kunming University of Science and Technology, Kunming, 650500, PR China

    2 shared publications
  • Jingjing Li

    Biotherapy Center State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People's Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Optimal Adjuvant Therapy Selection for Chinese BRAF V600‐Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies

    by Rongcheng Zhang, Yao Liang, Jingjing Li, Qianqi Chen, Ya Ding, Xizhi Wen, Baiwei Zhao, Wei Zheng, Junwan Wu, Qiong Zhang, et al.

    While adjuvant immunotherapy and BRAF/MEK inhibitors improve the outcomes for BRAF V600‐mutant stage III melanoma, comparisons of long‐term survival and safety of these therapeutic modalities are currently lacking in Chinese patients. We retrospectively analyzed data from patients with resected stage III BRAF V600‐mutant melanoma who received adjuvant therapy between June 2013 and December 2023 across three centers in China. Note that 122 patients were included and categorized into interferon ( n = 25), aPD‐1 ( n = 18), D/T ( n = 62), and BRAFi/aPD‐1 ( n = 17) cohorts. The D/T group demonstrated a significantly longer median RFS compared to the interferon and aPD‐1group (22.7 vs. 11.9 months, p = 0.005; vs. 12.5 months, p < 0.001). Similar results were obtained by restricted‐mean‐survival‐time model. Patients who continued D/T beyond 1 year exhibited significantly improved RFS and DMFS compared to those who discontinued at 1 year duration (NR vs. 22.0 months, p = 0.048; NR vs. 22.5 months, p = 0.026). NOTCH4 and IL7R mutations may serve as prognostic and predictive biomarkers for long‐term survival and targeted‐immunotherapy efficacy, respectively. Adjuvant therapy with D/T may represent the most effective treatment strategy for Chinese patients with stage III melanoma harboring BRAF V600 mutations. A combination of BRAF‐targeted therapy and aPD‐1 immunotherapy provided comparable efficacy and may be an alternative for a specific patient.

  • Top Cited Papers
    Open Access

    Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response

    by Zhaoqi Zhang, Ying Wang, Wei Yin, Qingyang Lei, Yuqiao Fu, Yingzi Liang, Ruilei Li, Ke Li

    Background: Skin cutaneous melanoma (SKCM) is a highly invasive cancer with dismal prognosis. Integrated stress response (ISR) is associated with tumorigenesis and progression, but its relationship with SKCM prognosis is unclear. This research aimed to identify relevant prognostic genes for SKCM prognosis and treatment insights. Methods: Data were obtained from public databases. Differential expression and regression analyses were used to identify prognostic genes. Based on these genes and independent prognostic factors, risk models and nomograms were constructed to assess their clinical application potential in SKCM. Then, immune microenvironment changes in SKCM were explored according to risk-group grouping, providing a basis for stratified treatment decisions for SKCM patients. Finally, RT-qPCR was used to validate the results. Results: DTL , DTX3L , KCNMB1 , NDRG1 , GPX2 , DERL3 and MBTPS2 were validated as prognostic genes. A risk model was constructed to classify patients into High Risk Group (HRG) and Low Risk Group (LRG), with high-risk SKCM patients having a higher mortality rate. A nomogram integrating clinical indicators was an effective SKCM survival prediction tool. The immune microenvironment differed significantly between risk groups, and most differentially infiltrated immune cells had higher infiltration levels in the Low Risk Group (LRG). Immunotherapy analysis suggested that the Low Risk Group (LRG) might benefit little from treatment, highlighting the need for stratified treatment of SKCM patients. RT-qPCR showed that prognostic genes were up-regulated in human melanoma cells compared to fibroblasts. Conclusion: The identification of ISR-featured prognostic genes and risk score stratification provide new insights into targeting SKCM and enhancing the efficacy of immunotherapy.


  • Open Access

    Addition of anti‐PD‐1 immunotherapy to BRAF inhibitor‐based targeted therapy improves real‐world survival and delays brain metastases in patients with BRAFV600‐mutant advanced melanoma: a multicenter cohort study

    by Junwan Wu, Qiuyue Ding, Qiong Zhang, Qianqi Chen, Xizhi Wen, Ya Ding, Jingjing Li, Ziluan Chen, Tao Zhang, Jiuhong Wang, et al.

    Anti‐PD‐1 immunotherapy and targeted therapy (TT) represent two major therapeutic modalities for BRAFV600‐mutant advanced melanoma, but the efficacy of combination therapy in Asian populations remains unknown. Asian melanoma patients differ significantly from Caucasians in tissue subtypes, pathogenesis and response to treatment. We retrospectively analyzed data of BRAFV600‐mutant advanced melanoma patients treated with first‐line vemurafenib (V) ± anti‐PD‐1 or dabrafenib+trametinib (D+T) ± anti‐PD‐1 between 2014 and 2023 from three centers in China. 178 patients were included, with V (n = 45), D+T (n = 51), V+anti‐PD‐1 (n = 39) and D+T+anti‐PD‐1 (n = 43). The median PFS (21.9 vs. 11.1 months, p < 0.001), OS (NR vs. 32.6 months, p = 0.027), and DoR (20.0 vs. 8.4 months, p = 0.002) were significantly prolonged with D+T+anti‐PD‐1 versus D+T. Addition of anti‐PD‐1 to V also significantly prolonged PFS, OS, and DoR (p < 0.001). V+anti‐PD‐1 was superior to D+T in terms of PFS (15.0 vs. 11.1 months, p = 0.007) and DoR (18.0 vs. 8.4 months, p = 0.013), and was comparable to D+T+anti‐PD‐1. Addition of anti‐PD‐1 to BRAF inhibitor‐based TT was associated with lower incidence of brain metastases (p = 0.032). Addition of anti‐PD‐1 to BRAF inhibitor‐based TT appears to be a safe and effective treatment option, conferring a survival benefit and delaying the onset brain metastases in patients with BRAFV600‐mutant advanced melanoma.


  • Open Access

    Causal association between skin cancer and immune cells: mendelian randomization (MR) study

    by Wei Yin, Ruilei Li, Zhaoqi Zhang, Ying Wang, Xinghua Tang, Lin Zhu, Hong Yao, Ke Li

    Background: Numerous meta-analyses and clinical studies have shown that subtypes of immune cells are associated with the development of skin cancer, but it is not clear whether this association is causal or biased. Mendelian randomization (MR) analysis reduces the effect of confounding factors and improves the accuracy of the results when compared to traditional studies. Thus, in order to examine the causal relationship between various immune cell and skin cancer, this study employs two-sample MR. Methods: This study assesses the causal association between 731 immune cell characteristics and skin cancer using a two-sample Mendel randomization (MR) methodology. Multiple MR methods were used to bias and to derive reliable estimates of causality between instrumental variables and outcomes. Comprehensive sensitivity analyses were used to validate the stability, heterogeneity and horizontal multiplicity of the results. Results: We discovered that potential causal relationships between different types of immune cells and skin cancer disease. Specifically, one type of immune cell as potentially causal to malignant melanoma of skin (MM), eight different types of immune cells as potentially causal to basal cell carcinoma (BCC), four different types of immune cells as potentially causal to actinic keratosis (AK), and no different types of immune cells were found to have a potential causal association with squamous cell carcinoma(SCC), with stability in all of the results. Conclusion: This study demonstrates the close connection between immune cells and skin cancer disease by genetic means, which enriches the current knowledge about the role of immune cells in skin cancer and also contributes to the design of therapeutic strategies from an immunological perspective.


  • Open Access

    Causal Association between Skin Cancer and Immune Cells: Mendelian randomization (MR) study

    by Wei Yin¹, Ruilei Li¹, Zhaoqi Zhang¹, Ying Wang¹, Xinghua Tang¹, Lin Zhu¹, Hong Yao¹, Ke Li¹

    Background:Numerous meta-analyses and clinical studies have shown that subtypes of immune cells are associated with the development of skin cancer, but it is not clear whether this association is causal or biased. Mendelian randomization (MR) analysis reduces the effect of confounding factors and improves the accuracy of the results when compared to traditional studies. Thus, in order to examine the causal relationship between various immune cell and skin cancer, this study employs two-sample MR. Methods:This study assesses the causal association between 731 immune cell characteristics and skin cancer using a two-sample Mendel randomization (MR) methodology. Multiple MR methods were used to bias and to derive reliable estimates of causality between instrumental variables and outcomes. Comprehensive sensitivity analyses were used to validate the stability, heterogeneity and horizontal multiplicity of the results. Results:We discovered that potential causal relationships between different types of immune cells and skin cancer disease. Specifically, one type of immune cell as potentially causal to malignant melanoma of skin (MM), eight different types of immune cells as potentially causal to basal cell carcinoma (BCC), four different types of immune cells as potentially causal to actinic keratosis (AK), and no different types of immune cells were found to have a potential causal association with squamous cell carcinoma(SCC), with stability in all of the results. Conclusion:This study demonstrates the close connection between immune cells and skin cancer disease by genetic means, which enriches the current knowledge about the role of immune cells in skin cancer and also contributes to the design of therapeutic strategies from an immunological perspective.

  • Open Access

    Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

    by Long Chen, Fukun Chen, Huatao Niu, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Rong Huang, Ke Li, Yujie Lei, et al.

    Different from surgery, chemical therapy, radio-therapy and target therapy, Chimeric antigen receptor-modified T (CAR-T) cells, a novel adoptive immunotherapy strategy, have been used successfully against both hematological tumors and solid tumors. Although several problems have reduced engineered CAR-T cell therapeutic outcomes in clinical trials for the treatment of thoracic malignancies, including the lack of specific antigens, an immunosuppressive tumor microenvironment, a low level of CAR-T cell infiltration into tumor tissues, off-target toxicity, and other safety issues, CAR-T cell treatment is still full of bright future. In this review, we outline the basic structure and characteristics of CAR-T cells among different period, summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for thoracic malignancies, and point out the current challenges and new strategies, aiming to provide new ideas and approaches for preclinical experiments and clinical trials of CAR-T cell therapy for thoracic malignancies.


  • Open Access

    Identification of Key Genes Related to Lung Cancer with Brain Metastasis through Weighted Gene Correlation Network Analysis

    by Huatao Niu, Honghua Cao, Xin Liu, Pin Zuo, Yanbei Chen, Zhaojin Cheng, Ke Li, Yunchao Huang

    Background: Brain metastases (BM) are the most common malignant tumors affecting the human central nervous system, more than 50% of BM are lung cancer. However, there is currently no universal and effective screening tool for lung cancer with BM. The study aimed to identify key genes of lung cancer with BM, achieving early and accurate diagnosis of lung cancer with BM and long-term monitoring of the therapeutic response.Methods: RNA-seq data and related clinical information were downloaded from the Gene Expression Omnibus (GEO) database. The weighted gene co-expression network (WGCNA) analysis was performed using WGCNA package and MEtuequois module was considered as the highest correlation. The Limma package of R was used to obtain differentially expressed genes (DEGs) between lung cancer with BM and healthy samples. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichments of DEGs were analysed. LASSO and SVM were used to derive key genes for lung cancer with BM, and survival analysis was used to verify the correlation between the outcome and the key genes that we found. Key genes are annotated by GSEA, and CIBERSORT was used to calculate immune infiltration from samples.Results: 5 co-expression modules were detected, and ME turquois was most significantly associated with BM in lung cancer. These genes were mainly enriched in biological processes related to cell adhesion and immunity, and the main signaling pathways are significantly related to disease and cell adhesion. 4 BM-related key genes (AQP1, GSTA1, ROS1, TGFB1I1) were identified by LASSO regression analysis and SVM-RFE screening, they were demonstrated as the potential markers for lung cancer with BM. Immune cell infiltration revealed that they were negatively correlated with T cells regulatory, T cells CD8 and Mast cells activated. Overall survival correlation analysis confirmed that the expression of AQP1, GSTA1 and TGFB1I1 was negatively correlated with the prognosis of lung cancer patients, ROS1 was positively correlated with the prognosis of patients.Conclusions: AQP1, GSTA1, TGFB1I1 and ROS1 were identified as key genes of lung cancer with BM patients, which may regulate cancer progression by regulating immunity and have potential prognostic effects.

  • Open Access

    Long non‐coding RNA SNHG6 promotes the growth and invasion of non‐small cell lung cancer by downregulating miR‐101‐3p

    by Ke Li, Yongxin Jiang, Xudong Xiang, Quan Gong, Chunyan Zhou, Lijuan Zhang, Qianli Ma, Li Zhuang

    Background: The aim of this study was to determine the function of long non‐coding RNA small nucleolar RNA host gene 6 (SNHG6) in non‐small cell lung cancer (NSCLC) and its underlying mechanisms.Methods: The association of SNHG6 or miR‐101‐3p with clinicopathological characteristics and prognosis in patents with NSCLC was assessed by TCGA dataset. Cell proliferation and invasion were evaluated by MTT and Transwell assays and SNHG6‐specific binding with miR‐101‐3p was verified by bioinformatic analysis, luciferase gene report and RNA immunoprecipitation assays. qRT‐PCR and Western blot was used to assess the effects of SNHG6 on the expression of miR‐101‐3p and chromodomain Y like (CDYL) in NSCLC cells. A xenograft tumor model in vivo was established to observe the effects of SNHG6 knockdown on tumor growth.Results: We found that increased expression of SNHG6 was associated with pathological stage and lymph node infiltration, and acted as an independent prognostic factor of tumor recurrence in patients with NSCLC. Silencing SNHG6 expression repressed cell growth and invasion in vitro and in vivo, but overexpression of SNHG6 reversed these effects. Furthermore, SNHG6 was identified to act as a sponge of miR‐101‐3p, which could reduce cell proliferation and attenuate SNHG6‐induced CDYL expression. Low expression of miR‐101‐3p or high expression of CDYL was related to poor survival in patients with NSCLC.Conclusions: Our findings demonstrated that lncRNA SNHG6 contributed to the proliferation and invasion of NSCLC by downregulating miR‐101‐3p.


  • Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking

    by Yongqiang Zhao, Feifei Liu, Guojing He, Ke Li, Changcheng Zhu, Wei Yu, Conghai Zhang, Mingjin Xie, Jun Lin, Jihong Zhang, et al.


  • Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase

    by Xu Yuan, Qingyi Yang, Tongyan Liu, Ke Li, Yuwen Liu, Changcheng Zhu, Zhiyun Zhang, Linghua Li, Conghai Zhang, Mingjin Xie, et al.